<DOC>
	<DOCNO>NCT00220766</DOCNO>
	<brief_summary>The objective study determine safety tolerability Immune Globulin Intravenous ( Human ) , 10 % caprylate/chromatography ( IGIV-C ) purify similar infused two different infusion rate . The primary objective compare incidence severity infusion related adverse event IGIV-C , 10 % administer rate 0.14 mL/kg/min compare rate 0.08 mL/kg/min single daily infusion .</brief_summary>
	<brief_title>Rapid Infusion Immune Globulin Intravenous ( Human ) In Primary Immunodeficiency Patients</brief_title>
	<detailed_description>This prospective , single blind , randomize , multi-center cross-over trial patient Primary Immune Deficiency . Patients confirm diagnosis primary Immune Deficiency treat two daily infusion give 3-4 week apart fix individual IGIV dose regimen ( 400-600 mg/kg ) establish prior entry study . Any subject establish dose range 200-399 mg/kg assign receive 400 mg/kg course study dose schedule establish prior entry study . After screen period last four week , patient randomize one two cross-over group . Patients randomize Group 1 receive first IGIV-C , 10 % dose rate 0.08 mL/kg/min second infusion rate 0.14 mL/kg/min , whereas patient randomize Group 2 receive IGIV-C , 10 % rate 0.14 mL/kg/min first infusion day 0.08 mL/kg/min second infusion day . All patient prior IGIV-C , 10 % infusion receive volume 5 % dextrose calculated IGIV-C , 10 % infusion give target rate accord schema . Group 1 : - Infusion # 1 ( Week 0 ) Dextrose ( 0.14 mL/kg/min ) , IGIV-C , 10 % ( 0.08 mL/kg/min ) - Infusion # 2 ( Week 3-4 ) Dextrose ( 0.08 mL/kg/min ) , IGIV-C , 10 % ( 0.14 mL/kg/min ) Group 2 : - Infusion # 1 ( Week 0 ) Dextrose ( 0.08 mL/kg/min ) , IGIV-C , 10 % ( 0.14 mL/kg/min ) - Infusion # 2 Dextrose ( 0.14 mL/kg/min ) , IGIV-C , 10 % ( 0.08 mL/kg/min )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Confirmed diagnosis primary immune deficiency medical record available retrospective review least 3 month prior entry trial Signed inform consent write informed consent prior initiation study relate procedure Receiving regular infusion IGIV fix interval dosage ( range 200600 mg/kg give every 34 week ) least three month prior entry trial . Patients currently receive less 400 mg/kg eligible trial time study enrollment treat 400 mg/kg History suspicion significant allergic reaction intravenous immune globulin , and/or blood product Documented history selective IgA deficiency ( serum level &lt; 5.0 mg/dL ) know antibody IgA Isolated IgG subclass deficiency normal total serum IgG level Other condition may interfere trial , include patient demeanor mental ability follow instruction . Pretreatment antipyretic antihistamine Congestive heart failure ( New York Heart Association stage great Class II ) Renal insufficiency ( creatinine &gt; 2.5 mg/dL ) Conditions whose symptom effect could alter protein catabolism and/or IgG utilization ( e.g . proteinlosing enteropathy , nephrotic syndrome ) Pretreatment routinely require control/ameliorate IGIV infusionrelated adverse event ( AEs ) Any patient require IGIV dose frequently every 3 week maintain adequate trough level Women child bear potential practice adequate contraception ( i.e . chemical mechanical method ) pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Primary Immune Deficiency</keyword>
	<keyword>IGIV</keyword>
	<keyword>Immunoglobulin G</keyword>
</DOC>